New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation

Walid E. Elgammal, Hazem Elkady, Reda G. Yousef, Wagdy M. Eldehna, Dalal Z. Husein, Fatma G. Amin, Bshra A. Alsfouk, Eslam B. Elkaeed, Ibrahim H. Eissa and Ahmed M. Metwaly

RSC Adv., 2025, 15, 14477
DOI: 10.1039/D5RA01223F

Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors

Walid E. Elgammal, Hazem Elkady, Mohammed A. Dahab, Hazem A. Mahdy, Mohamed Hagras, Ahmed Nofal, Bshra A. Alsfouk, Eslam B. Elkaeed, Ibrahim H. Eissa and Ahmed M. Metwaly

Future Medicinal Chemistry, 2025, 17, 915
DOI: 10.1080/17568919.2025.2485863

New 1,3,4‐Thiadiazole‐Based Dual B‐Raf/VEGFR‐2 Inhibitors With Potential Anti‐Breast Activity: Design, Synthesis, In Vitro and In Silico Evaluations

Walid E. Elgammal, Hazem Elkady, Hazem A. Mahdy, Bshra A. Alsfouk, Dalal Z. Husein, Fatma G. Amin, Abdelrahman A. Abuelkhir, Eslam B. Elkaeed, Ahmed M. Metwaly and Ibrahim H. Eissa

Archiv der Pharmazie, 2025, 358
DOI: 10.1002/ardp.70097

Computational and biological evaluation of palladium(II) complexes as VEGFR-2 inhibitors: a molecular docking, dynamics, and cytotoxicity study

Tuncay Karakurt, Büşra Kaya, Onur Şahin, Elif Avcu Altıparmak, Tülay Bal-Demirci and Bahri Ülküseven

Inorganic Chemistry Communications, 2026, 184, 115860
DOI: 10.1016/j.inoche.2025.115860

Novel Sulfonamide Derivatives as Anticancer Agents, VEGFR-2 Inhibitors, and Apoptosis Triggers: Design, Synthesis, and Computational Studies

Shatha Hallal Al-Ziyadi, Ahmed H. Halawa, Amany Belal, Nisreen Khalid Aref Albezrah, Ahmad J. Obaidullah, Nashwa S. Abdelshafi, Hossa F Al-Shareef, Ahmed B. M. Mehany, Saber M. Hassan and Walid E. Elgammal

ACS Omega, 2025, 10, 39772
DOI: 10.1021/acsomega.5c03503

Integrated computational and biological evaluations of newly synthesized thiadiazole-based VEGFR-2 inhibitors with targeted anti-breast cancer activity

Bshra A. Alsfouk, Walid E. Elgammal, Hazem Elkady, Hazem A. Mahdy, Dalal Z. Husein, Omar A. Soliman, Abdelrahman A. Abuelkhir, Ibrahim H. Eissa, Eslam B. Elkaeed and Ahmed M. Metwaly

Naunyn-Schmiedeberg's Arch Pharmacol, 2026, 399, 953
DOI: 10.1007/s00210-025-04439-7

Microwave-assisted green synthesis, in silico evaluation, and in vitro antimicrobial activity of novel 1,3,4-thiadiazole-s-triazine hybrids

Em Canh Pham, Bich-Ngoc Thi Le, Thu Anh Pham, Thao Thanh Vu, Tuoi Thi Hong Do and Tuyen Ngoc Truong

Journal of Molecular Structure, 2026, 1357, 145121
DOI: 10.1016/j.molstruc.2025.145121

2,3-Dihydro-1,3,4-thiadiazoles as dual B-Raf / VEGFR-2 inhibitors: Design, synthesis, and anti-breast cancer assessment

Walid E. Elgammal, Hazem Elkady, Hazem A. Mahdy, Alaa Elwan, Dalal Z. Husein, Fatma G. Amin, Bshra A. Alsfouk, Eslam B. Elkaeed, Ibrahim H. Eissa and Ahmed M. Metwaly

Journal of Molecular Structure, 2026, 1354, 144717
DOI: 10.1016/j.molstruc.2025.144717

Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis induction

Eslam B. Elkaeed, Walid E. Elgammal, Hazem Elkady, Hazem A. Mahdy, Aisha A. Alsfouk, Dalal Z. Husein, Omar A. Soliman, Mariam Omara, Ibrahim H. Eissa and Ahmed M. Metwaly

Future Medicinal Chemistry, 2025, 17, 2145
DOI: 10.1080/17568919.2025.2552639

Design, synthesis, biological evaluation and in-silico study of thioether-linked 4-hydroxycoumarin-benzothiazole derivatives targeting EGFR for cancer therapy

Sanket Bora, Pallavi Patil, Mahavir Chhajed and Mohamad Taleuzzaman

Discov. Chem., 2025, 2
DOI: 10.1007/s44371-025-00369-8

Innovative Nicotinamide‐Dihydrothiadiazole Compounds for Targeting VEGFR‐2: Design, Synthesis, and Mechanistic Exploration in Breast Cancer Treatment

Ahmed M. Metwaly, Hazem Elkady, Walid E. Elgammal, Reda G. Yousef, Dalal Z. Husein, Omar A. Soliman, Mohamed Hagras, Bshra A. Alsfouk, Eslam B. Elkaeed and Ibrahim H. Eissa

ChemistrySelect, 2025, 10
DOI: 10.1002/slct.202501319

Development of New Thiadiazole Derivatives as VEGFR‐2 Inhibitors With Anticancer and Proapoptotic Activities‏

Hazem Elkady, Walid E. Elgammal, Mohamed M. Khalifa, Hazem A. Mahdy, Ahmed S. Ibrahim, Abdullah Y. Saad, Bshra A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly and Ibrahim H. Eissa

Archiv der Pharmazie, 2025, 358
DOI: 10.1002/ardp.70042

Design and synthesis of pyrazolopyrimidinone derivatives as dual VEGFR/Aurora kinase inhibitors against hepatocellular and breast carcinomas

Kurls E. Anwer, Botros Y. Beshay, Marium M. Shamaa, Nour E.A. Abd El-Sattar and Amira Senbel

Biomedicine & Pharmacotherapy, 2025, 192, 118679
DOI: 10.1016/j.biopha.2025.118679

Synthesis, structural features, computational study along with molecular docking examination of organosulfur mercaptoacetic acid based compound

Sabiya Osmanova, Malahat Kurbanova, Muhammad Ashfaq, Mehran Feizi-Dehnayebi, Muhammad Nawaz Tahir and Onur Şahin

Struct Chem, 2025
DOI: 10.1007/s11224-025-02668-3

Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors

Ibrahim H. Eissa, Hazem Elkady, Walid E. Elgammal, Hazem A. Mahdy, Hany S. Elshennawy, Dalal Z. Husein, Fatma G. Amin, Ibrahim M. Ibrahim, Bshra A. Alsfouk, Eslam B. Elkaeed and Ahmed M. Metwaly

Future Medicinal Chemistry, 2025, 17, 1023
DOI: 10.1080/17568919.2025.2498879

A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy

Ibrahim H. Eissa, Hazem Elkady, Walid E. Elgammal, Hazem A. Mahdy, Dalal Z. Husein, Fatma G. Amin, Asmaa A. A. Elsheshiny, Shimaa. S. Abdelfattah, Aisha A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly and Afzal Basha Shaik

PLoS One, 2025, 20, e0328305
DOI: 10.1371/journal.pone.0328305